---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-125694"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2023-12-13T23:59:59+00:00"
generated_at: "2026-06-07T13:27:12.330649+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# VYNE shareholders approve 2023 Equity Incentive Plan; CEO granted 225K RSUs and options

## Summary
- Stockholders approved 2023 Equity Incentive Plan authorizing 2,099,856 shares, effective Dec 13, 2023.
- CEO David Domzalski receives 225,000 RSUs and options for 225,000 shares on Dec 13, 2023, and another 225,000 RSUs and options on Jan 1, 2024.
- Each of three other named executives (Harsch, Stuart, Zeronda) gets 62,500 RSUs and 62,500 options on both Dec 13 and Jan 1.
- Annual meeting results: Sharon Barbari elected director; Baker Tilly ratified as auditor for FY2023.
- Equity awards vest over four years; option exercise price equals closing price on grant date.

## SEC filing metadata
- accession: 0001104659-23-125694
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2023-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465923125694/0001104659-23-125694-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465923125694/tm2332768d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-125694
- JSON: https://secwatch.observer/filing/0001104659-23-125694.json
- Plain text: https://secwatch.observer/filing/0001104659-23-125694.txt

## Key facts
- Shareholder Votes
  VYNE Therapeutics Inc. shareholders approved Ratification of appointment of Baker Tilly US, LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-12-13 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-12-13
  source text: Proposal 2 . The stockholders ratified the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 10,666,683 113,944 27,178 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465923125694/0001104659-23-125694-index.htm
- Shareholder Votes
  VYNE Therapeutics Inc. shareholders approved Approval of the 2023 Plan at the 2023-12-13 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-12-13
  source text: Proposal 3 . The stockholders approved the 2023 Plan. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 9,650,797 204,128 7,253 945,627
  evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465923125694/0001104659-23-125694-index.htm
- Shareholder Votes
  VYNE Therapeutics Inc. shareholders approved Election of director Sharon Barbari at the 2023-12-13 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-12-13
  source text: Proposal 1 . The stockholders elected the following director to the Board, to hold office until the 2026 annual meeting of stockholders or until her successor is elected. The voting results were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Sharon Barbari 9,678,059 184,119 945,627
  evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465923125694/0001104659-23-125694-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.